Nostos Genomics raised €5M in a seed round backed by 42CAP, Frontline Ventures, Amino Collective and Entrepreneur First.

Nostos Genomics, a Berlin, Germany-based sofwtaer startup developing a genetic analysis platform, announced completing a seed funding round closed at €5M ($5.7M).

The money was raised from investors including 42CAP, Frontline Ventures, Amino Collective and Entrepreneur First.

Nostos Genomics, founded in 2018 by David Gorgan and Rocío Acuña-Hidalgo, is developing genetic disease identification technology - AION - which is able to identify gene variants responsible for more than 10,000 diseases. As a result, diagnosis time is cut from on average 12 hours to within two minutes. In addition to significantly cutting costs and improving accessibility for testing, its fully automated solution increases the process accuracy and reduces the chance of misdiagnosis.

The company’s CE-IVD certified procedure has already been launched Europe-wide, patent proceedings for Nostos technology are pending in the U.S. Currently, data from Genomics England is being used for a large-scale validation study.

Nostos Genomics was previously pre-seeded in 2020.